Bertuccio Francesco Rocco, Montini Simone, Fusco Maria Antonietta, Di Gennaro Antonella, Sciandrone Gaetano, Agustoni Francesco, Galli Giulia, Bortolotto Chandra, Saddi Jessica, Baietto Guido, Melloni Giulio, D'Ambrosio Gioacchino, Corsico Angelo Guido, Stella Giulia Maria
Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy.
Unit of Respiratory Diseases, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
Cancers (Basel). 2025 Mar 30;17(7):1160. doi: 10.3390/cancers17071160.
Pleural mesothelioma (PM) is a rare and highly aggressive cancer which arises from mesothelial layer and primarily linked to asbestos exposure, genetic predispositions, and specific mutations. Despite current treatment modalities, including chemotherapy, antiangiogenic therapy and more recently immunotherapy, the prognosis remains dismal, with a median survival time of 6-18 months.
The urgent need for novel therapeutic strategies has prompted research into molecular targets and precision medicine approaches. At present, many potential targets for therapeutic strategies have been identified, and emerging clinical trials are demonstrating certain clinical efficacy.
This review examines advancements in understanding PM's genetic and epigenetic landscape, signaling pathways, and promising therapeutic targets.
We also discuss the results of recent clinical trials and their potential implications for future treatment paradigms.
胸膜间皮瘤（PM）是一种罕见且侵袭性很强的癌症，起源于间皮细胞层，主要与接触石棉、遗传易感性和特定突变有关。尽管目前有化疗、抗血管生成治疗以及最近的免疫治疗等治疗方式，但预后仍然很差，中位生存时间为6至18个月。
对新型治疗策略的迫切需求促使人们对分子靶点和精准医学方法进行研究。目前，已经确定了许多治疗策略的潜在靶点，正在进行的临床试验也显示出一定的临床疗效。
本综述探讨了在了解PM的遗传和表观遗传格局、信号通路以及有前景的治疗靶点方面取得的进展。
我们还讨论了近期临床试验的结果及其对未来治疗模式的潜在影响。
